EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Alnylam Pharmaceuticals, Inc (A1LN34) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Alnylam Pharmaceuticals, Inc BRL 48.74, price BRL 57.48, upside -15.2%, quality 67 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · BR · ISIN US02043Q1076

AP Broad data Oct 3, 2026

Alnylam Pharmaceuticals, Inc

A1LN34 · SA

Overvalued / MonitorQuality growthQuality is not strong enough to offset the price risk.

!Fair value R$48.74 · Overvalued (−15.2%)
✓Quality 67/100
✓Healthy Growth (revenue 3y +53.0 %/yr)
✓Solidly profitable · 12.6% net margin (TTM)
!High debt · generates free cash flow
✓Wide moat 72/100

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

R$132.40 R$29.85 Fair Value R$48.74 Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range R$29.85 – R$132.40 · fair‑value band R$23.02 – R$74.18 · the R$57.48 price screens above the R$48.74 fair value. Dashed = 300-day average. As of Oct 3, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

Show more

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Stock analysis

Alnylam Pharmaceuticals, Inc (A1LN34) currently trades at R$57.48, while our model-based Fair Value estimate is R$48.74, 15.2% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of R$28.51 per share, and 0 of the 24 models we run sit above the R$57.48 price.

Bear case: the Economic Profit group reads lowest at R$6.75, and 24 of the 24 models stay below the price. Evidence for this calculation is high.

Scenario range: R$23.02 (bear) to R$74.18 (bull), the price of R$57.48 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Alnylam Pharmaceuticals, Inc reported revenue of $3.7B in FY2025 versus $1.0B in FY2022, a compound +53.0%/yr. Reported net income was $314M in FY2025.

Key figures

Market cap R$164B (≈ $31.3B) · P/E ratio 55.8 · P/S ratio 4.71 · EPS (TTM) R$1.03 · Net margin 8.4% · Return on equity 90.4% · Return on assets (EBIT) −6.6% · Operating margin 23.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 57% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −15%, A1LN34 screens richer than that median.

Fair Value models

Bear R$23.02 Fair Value R$48.74 Bull R$74.18
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (R$0.7788 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV R$5.15 R$6.28 R$7.26 71
FCF DCF R$20.28 R$32.84 R$72.81 69
Growth DCF R$18.98 R$39.26 R$72.48 69
All 24 models by family
DCF Models
FCF DCF R$20.28 R$32.84 R$72.81 69
Owner Earnings R$14.06 R$34.04 R$76.00 65
5Y Revenue Exit R$11.00 R$18.82 R$35.09 65
5Y EBITDA Exit R$12.37 R$21.60 R$39.64 67
5Y P/E Exit R$12.03 R$26.24 R$45.14 63
10Y Revenue Exit R$13.55 R$28.45 R$36.91 62
10Y EBITDA Exit R$14.92 R$31.40 R$58.91 60
10Y P/E Exit R$14.67 R$30.67 R$55.93 56
Earnings-Based
Graham-Dodd R$4.17 R$29.10 R$40.84 59
Lynch FV R$15.03 R$21.48 R$27.92 57
PEG = 1.0 R$15.03 R$21.48 R$27.92 53
EPV R$5.15 R$6.28 R$7.26 71
Multiples
P/E Multiple R$10.12 R$13.50 R$16.87 63
P/S Multiple R$7.82 R$10.43 R$13.04 58
P/B Multiple R$5.21 R$6.95 R$8.68 55
EV/EBIT R$9.84 R$13.66 R$17.47 66
EV/EBITDA R$8.97 R$12.49 R$16.01 67
EV/Revenue R$6.57 R$10.07 R$13.57 53
Asset-Based
NCAV (Graham) R$0.7700 R$1.03 R$1.54 54
Growth DCF
Growth DCF R$18.98 R$39.26 R$72.48 69
Rev-Margin DCF R$12.23 R$21.79 R$41.90 64
Economic Profit
Residual Income R$4.08 R$6.75 R$19.10 55
ROIC Compounder R$7.74 R$13.84 R$17.55 66
Growth Earnings
Growth-Adj P/E R$19.96 R$28.51 R$37.06 63

Open the full fair value analysis →

Notify me when A1LN34 reaches fair value

Put A1LN34 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 67/100

Of which business quality 64 · Market factors (momentum, volatility) 19

Profitability 68
Margins and returns on capital today
Quality Growth 78
Are margins and returns improving?
Cashflow 70
Earnings quality: real cash, not paper profit
Fin. Strength 47
Balance sheet, leverage, solvency risk
Investment 70
Disciplined investing over empire-building
Low Volatility 52
Calm price path (market factor)
Momentum 6
Price trend over the last 3–12 months (market factor)
52W Momentum 4
Distance to the 52-week high (market factor)
Net Issuance 58
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+65.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+53.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−83.1% (2022) → 12.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−29.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+26.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −31.3% a year for the price and +23.7% for the forecasts.
Forecast 2026 (sales)+47.9%
Forecast 2027 (sales)+26.4%
Projected 2028 (sales)+23.4%
Projected 2029 (sales)+20.3%
Projected 2030 (sales)+17.3%

A1LN34 screens overvalued: fair value 15% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Alnylam Pharmaceuticals, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%
Incyte Corporation INCY $124.82 $201.35 +61%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Alnylam Pharmaceuticals, Inc · Fair Value
R$48.74 −15%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Alnylam Pharmaceuticals, Inc Fair Value". https://www.fairvalue-calculator.com/stock/A1LN34

Frequently asked questions

Is Alnylam Pharmaceuticals, Inc (A1LN34) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of R$48.74 versus a price of R$57.48, about −15% upside (overvalued).
What is the fair value of A1LN34?
Our model-based fair value for Alnylam Pharmaceuticals, Inc is R$48.74 (as of Oct 3, 2026), built from audited fundamentals. The current price: R$57.48.
What is the quality score of A1LN34?
Alnylam Pharmaceuticals, Inc has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Alnylam Pharmaceuticals, Inc (A1LN34)?
Our model-based price target is the fair value of R$48.74 (as of Oct 3, 2026) from 24 valuation models. Cautious scenario R$23.02, optimistic scenario R$74.18. It is a calculation from audited fundamentals, not an analyst target.
What is the Alnylam Pharmaceuticals, Inc stock forecast for 2026?
Our models put fair value at R$48.74, about −15% upside versus a price of R$57.48 (overvalued). Cautious scenario R$23.02, optimistic scenario R$74.18. The calculation is refreshed regularly with new filings.
What is the revenue of Alnylam Pharmaceuticals, Inc (A1LN34)?
Alnylam Pharmaceuticals, Inc reported trailing-twelve-month revenue of about $4.3B (latest available figure, as of Oct 3, 2026).
What growth is priced into Alnylam Pharmaceuticals, Inc (A1LN34)?
For today's price to be fair in a discounted-cash-flow model, Alnylam Pharmaceuticals, Inc would have to grow free cash flow by -29.6 % per year for five years (discount rate 10.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +53.0 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of A1LN34 use?
Our models discount Alnylam Pharmaceuticals, Inc at 10.7 %: a base by market capitalisation (large), damped by beta 0.27, country premium for Brazil. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Alnylam Pharmaceuticals, Inc that is -29.6 % per year a year over ten years, using the same discount rate (10.7 %) and the same formula as our fair value.
How much growth has Alnylam Pharmaceuticals, Inc (A1LN34) delivered so far?
Over the past 3 years revenue at Alnylam Pharmaceuticals, Inc grew +53.0 % a year. The price currently implies -29.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Alnylam Pharmaceuticals, Inc (A1LN34) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into Alnylam Pharmaceuticals, Inc (-29.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Alnylam Pharmaceuticals, Inc (A1LN34)?
The free-cash-flow yield on the price is 31.94 %: that much free cash flow Alnylam Pharmaceuticals, Inc produces per unit of market value. When it exceeds the discount rate of our models (10.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Alnylam Pharmaceuticals, Inc (A1LN34)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Alnylam Pharmaceuticals, Inc it is R$48.74 per share (as of Oct 3, 2026), against a price of R$57.48. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Alnylam Pharmaceuticals, Inc stock overvalued or undervalued in 2026?
As of Oct 3, 2026, A1LN34 trades above its calculated fair value: price R$57.48, fair value R$48.74, a gap of about −15% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of A1LN34?
No. The price is what the market pays today (R$57.48); the fair value is what the company's own numbers justify (R$48.74). For Alnylam Pharmaceuticals, Inc the two are R$8.74 per share apart. That gap is exactly why we show both numbers side by side.
How much is Alnylam Pharmaceuticals, Inc worth?
The market values Alnylam Pharmaceuticals, Inc at about R$164B (market capitalisation, as of Oct 3, 2026). Per share that is R$57.48; our models calculate a fair value of R$48.74 per share.
What do the bullish and bearish scenarios say about A1LN34?
Our models span a range for Alnylam Pharmaceuticals, Inc: cautious scenario R$23.02, base R$48.74, optimistic R$74.18 per share (as of Oct 3, 2026, price R$57.48). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is A1LN34 from its 52-week high?
Alnylam Pharmaceuticals, Inc trades at R$57.48, about 57% below its 52-week high of R$132.40 and 14% above the low of R$50.25 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of R$48.74 is for.
Which stocks are comparable to Alnylam Pharmaceuticals, Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Alnylam Pharmaceuticals, Inc stock attractive at the current price?
The data as of Oct 3, 2026: price R$57.48, calculated fair value R$48.74 (−15%), Quality Score 67/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of A1LN34 calculated?
We run Alnylam Pharmaceuticals, Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$48.74, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Alnylam Pharmaceuticals, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Alnylam Pharmaceuticals, Inc (A1LN34)?
The closing price on Oct 2, 2026 was R$57.48. Our model-based fair value is R$48.74, about −15% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Alnylam Pharmaceuticals, Inc right now?
The model range is unusually wide (R$23.02 to R$74.18). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (67/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Alnylam Pharmaceuticals, Inc

How large is the market capitalisation of Alnylam Pharmaceuticals, Inc (A1LN34)?
The market capitalisation of Alnylam Pharmaceuticals, Inc is R$164B (≈ $31.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Alnylam Pharmaceuticals, Inc (A1LN34)?
The price-to-earnings ratio of Alnylam Pharmaceuticals, Inc is 55.8. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Alnylam Pharmaceuticals, Inc (A1LN34)?
The price-to-sales ratio of Alnylam Pharmaceuticals, Inc is 4.71 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Alnylam Pharmaceuticals, Inc (A1LN34)?
Earnings per share at Alnylam Pharmaceuticals, Inc are R$1.03 (price ÷ EPS = P/E 55.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Alnylam Pharmaceuticals, Inc (A1LN34)?
The net margin of Alnylam Pharmaceuticals, Inc is 8.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Alnylam Pharmaceuticals, Inc (A1LN34)?
The return on equity (ROE) of Alnylam Pharmaceuticals, Inc is 90.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Alnylam Pharmaceuticals, Inc (A1LN34)?
On an EBIT basis the return on assets of Alnylam Pharmaceuticals, Inc is −6.6% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Alnylam Pharmaceuticals, Inc (A1LN34)?
The operating margin of Alnylam Pharmaceuticals, Inc is 23.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Alnylam Pharmaceuticals, Inc (A1LN34)?
Revenue at Alnylam Pharmaceuticals, Inc is growing +96.4% versus a year earlier (3y avg +53.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Alnylam Pharmaceuticals, Inc (A1LN34) carry?
The net debt of Alnylam Pharmaceuticals, Inc is $58.2M (fiscal year 2024, ≈ 0.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.